EBMcalc Logo
   INTRO    EQUATIONS    CRITERIA    DECISION TREES    CONVERTERS    SPECIALTIES    OPTIMIZERS    REFS    SEARCH    PRESS ROOM   
 
  Gail Model for 5 Year Risk of Breast Cancer in Black Women (2007)

 
RelRisk = Menarche * NumBiops * AgeFLBNumRels * AtypHyper
FiveYearRisk = RelRisk * BaselineRiskForAge

 
Input:
 
Menarche Age at menarche ≥14 years old (1.00)

Age at menarche <14 years old (1.31)
Num Biops
Age FLB Num Rels
Atyp Hyper No biopsies (1.00)

At least one biopsy and no atypical hyperplasia found in any biopsy specimen (0.93)

No atypical hyperplasia found and hyperplasia status unknown for at least one biopsy specimen (1.00)

Atypical hyperplasia found in at least one biopsy specimen (1.82)
Baseline Risk For Age
Results:
 
Rel Risk  
Five Year Risk  
 
Decimal Precision  

 
     
 
Include literature references: Yes   No
 
Notes

 
Related Results
 
          
 

 
References
  1. Gail MH, Costantino JP, Pee D, et. al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007 Dec 5;99(23):1782-92. Epub 2007 Nov 27. PMID: 18042936 PubMed Logo
  2. Gail MH, Constantino JP, Bryant J, et. al. Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. J. National Cancer Institute. 1999; V91, #21, pages 1829-1846. PMID: 10547390 PubMed Logo
  3. Costantino JP, Gail MH, Pee D, et. al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8. PMID: 10491430 PubMed Logo
  4. EBMcalc CrossRef: Gail Model (1989 paper)
  5. EBMcalc CrossRef: Odds Ratio and Relative Risk
  6. EBMcalc CrossRef: Breast Cancer Local Recurrence Risk

 
Associated Medical Subject Headings [MeSH] Terms
 
         Adult,   African Americans,   Age Factors,   Aged,   Anticarcinogenic Agents,   Antineoplastic Agents,   Biopsy,   Bone,   Breast,   Breast Neoplasms,   Carcinoma,   Carcinoma in Situ,   Cataract,   Confounding Factors (Epidemiology),   Controlled Clinical Trials as Topic,   Counseling,   Ductal,   Education,   Endometrial Neoplasms,   Estrogen Receptor Modulators,   Female,   Forecasting,   Fractures,   Hormonal,   Humans,   Incidence,   Logistic Models,   Mammography,   Mass Screening,   Middle Aged,   Models,   National Institutes of Health (U.S.),   Neoplasm Invasiveness,   Odds Ratio,   Patient Education as Topic,   Pulmonary Embolism,   Raloxifene,   Reproducibility of Results,   Risk,   Risk Assessment,   Risk Factors,   SEER Program,   Selective Estrogen Receptor Modulators,   Statistical,   Stroke,   Tamoxifen,   Venous Thrombosis,   Women's Health

 
Associated ICD10-CM Codes
 
   C50.919Malignant neoplasm of unspecified site of unspecified female breast
   C50.819Malignant neoplasm of overlapping sites of unspecified female breast
   N63Unspecified lump in breast
   Z85.3Personal history of malignant neoplasm of breast
   D49.3Neoplasm of unspecified behavior of breast

 
Associated ICD9-CM Codes
 
   239.3Breast neoplasm nos
   V10.3Hx of breast malignancy
   611.72Lump or mass in breast
   174.8Malign neopl breast nec
   174.9Malign neopl breast nos

 
Legal Notices and Disclaimer

 
All information contained in and produced by the EBMcalc system is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease. THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER. Click here for full notice and disclaimer.
 
EBMcalc is Copyright © 1998-2017 Foundation Internet    [Build 254410 v17.3]